Literature DB >> 34846548

Evaluation of the terpenes β-caryophyllene, α-terpineol, and γ-terpinene in the mouse chronic constriction injury model of neuropathic pain: possible cannabinoid receptor involvement.

Joshua A Bilbrey1, Yuma T Ortiz1, Jasmine S Felix1, Lance R McMahon1, Jenny L Wilkerson2.   

Abstract

Pain is one of the most common reasons to seek medical attention, and chronic pain is a worldwide epidemic. Anecdotal reports suggest cannabis may be an effective analgesic. As cannabis contains the terpenes α-terpineol, β-caryophyllene, and γ-terpinene, we hypothesized these terpenes would produce analgesia in a mouse model of neuropathic pain. We used the chronic constriction injury of the sciatic nerve mouse model, which produces mechanical allodynia, assessed via the von Frey assay, as well as thermal hyperalgesia assessed via the hotplate assay. Compounds were further assessed in tests of locomotor activity, hypothermia, and acute antinociception. Each terpene produced dose-related reversal of mechanical allodynia and thermal hyperalgesia. Thermal hyperalgesia displayed higher sensitivity to the effects of each terpene than mechanical allodynia, and the rank order potency of the terpenes was α-terpineol > β-caryophyllene > γ-terpinene. To examine the involvement of cannabinoid receptors, further tests were conducted in mice lacking either functional cannabinoid type 1 receptors (CB1R (-/-)) or cannabinoid type 2 receptors (CB2R (-/-)). Compared to wild type mice, CB1R (-/-) mice treated with α-terpineol displayed a 2.91-fold decrease in potency to reverse mechanical allodynia; in CB2R (-/-) mice, the potency of α-terpineol was decreased 11.73-fold. The potency of β-caryophyllene to reverse mechanical allodynia decreased 1.80-fold in CB2R (-/-) mice. Each terpene produced a subset of effects in tests of locomotor activity, hypothermia, and acute antinociception. These findings suggest α-terpineol, β-caryophyllene, and γ-terpinene may have differential cannabinoid receptor activity and a pharmacological profile that may yield new efficacious analgesics.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cannabis; Chronic pain; Marijuana; Neuropathy; Polypharmacology

Mesh:

Substances:

Year:  2021        PMID: 34846548     DOI: 10.1007/s00213-021-06031-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  The effects of morphine methadone and meperidine on some reflex responses of spinal animals to nociceptive stimulation.

Authors:  S IRWIN; R W HOUDE; D R BENNETT; L C HENDERSHOT; M H SEEVERS
Journal:  J Pharmacol Exp Ther       Date:  1951-02       Impact factor: 4.030

2.  α-terpineol reduces mechanical hypernociception and inflammatory response.

Authors:  Makson G B de Oliveira; Rosemarie B Marques; Michele F de Santana; Amanda B D Santos; Fabíola A Brito; Emiliano O Barreto; Damião P De Sousa; Fernanda R C Almeida; Daniel Badauê-Passos; Angelo R Antoniolli; Lucindo J Quintans-Júnior
Journal:  Basic Clin Pharmacol Toxicol       Date:  2012-04-11       Impact factor: 4.080

Review 3.  Transgenic studies of pain and analgesia: mutation or background genotype?

Authors:  W R Lariviere; E J Chesler; J S Mogil
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

4.  The oral administration of trans-caryophyllene attenuates acute and chronic pain in mice.

Authors:  L I G Paula-Freire; M L Andersen; V S Gama; G R Molska; E L A Carlini
Journal:  Phytomedicine       Date:  2013-09-20       Impact factor: 5.340

5.  Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Authors:  P J Little; D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

Review 6.  Phytocannabinoids: a unified critical inventory.

Authors:  Lumír Ondřej Hanuš; Stefan Martin Meyer; Eduardo Muñoz; Orazio Taglialatela-Scafati; Giovanni Appendino
Journal:  Nat Prod Rep       Date:  2016-11-23       Impact factor: 13.423

7.  The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.

Authors:  A-L Klauke; I Racz; B Pradier; A Markert; A M Zimmer; J Gertsch; A Zimmer
Journal:  Eur Neuropsychopharmacol       Date:  2013-10-22       Impact factor: 4.600

8.  α-Terpineol reduces cancer pain via modulation of oxidative stress and inhibition of iNOS.

Authors:  Daniele Nascimento Gouveia; Janara Santos Costa; Marlange Almeida Oliveira; Thallita Kelly Rabelo; Ana Mara de Oliveira E Silva; Adriana Andrade Carvalho; Rodrigo Miguel-Dos-Santos; Sandra Lauton-Santos; Luciana Scotti; Marcus Tullius Scotti; Márcio Roberto Viana Dos Santos; Lucindo José Quintans-Júnior; Ricardo Luiz Cavalcanti De Albuquerque Junior; Adriana Gibara Guimarães
Journal:  Biomed Pharmacother       Date:  2018-06-11       Impact factor: 6.529

Review 9.  Neuropathic pain in the general population: a systematic review of epidemiological studies.

Authors:  O van Hecke; Sophie K Austin; Rafi A Khan; B H Smith; N Torrance
Journal:  Pain       Date:  2013-11-26       Impact factor: 6.961

10.  Beta-caryophyllene is a dietary cannabinoid.

Authors:  Jürg Gertsch; Marco Leonti; Stefan Raduner; Ildiko Racz; Jian-Zhong Chen; Xiang-Qun Xie; Karl-Heinz Altmann; Meliha Karsak; Andreas Zimmer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

  10 in total
  2 in total

1.  An Optimized Terpene Profile for a New Medical Cannabis Oil.

Authors:  Valentina Maggini; Lorenzo Calvi; Tommaso Pelagatti; Eugenia Rosaria Gallo; Celine Civati; Carlo Privitera; Flavio Squillante; Paolo Maniglia; Domenico Di Candia; Roberto Spampatti; Fabio Firenzuoli
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

2.  Editorial: Application of plant secondary metabolites to pain neuromodulation, volume II.

Authors:  Rajeev K Singla; Adriana Gibara Guimarães; Gokhan Zengin
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.